MiMedx Group Files 8-K: Bylaw Change and 2026 Annual Meeting Results

What Happened
MiMedx Group, Inc. (MDXG) filed an 8-K on June 16, 2026 reporting two corporate actions approved June 10, 2026: (1) the board amended the company’s Amended & Restated Bylaws to increase the number of public-company boards the CEO may serve on to three; and (2) the company held its 2026 Annual Meeting of Shareholders where shareholders re‑elected the named directors, approved an advisory (non-binding) resolution on executive compensation, and ratified Deloitte & Touche LLP as the independent auditor for fiscal 2026. A total of 125,360,965 shares (about 84.2% of votes entitled to be cast) were represented at the meeting.

Key Details

• Bylaw amendment: CEO may now sit on up to three public-company boards (approved by the Board on June 10, 2026).
• Shares represented at the meeting: 125,360,965 (≈84.2% of votes entitled to be cast).
• Director elections: shareholders re‑elected Joseph H. Capper; James L. Bierman; William A. Hawkins, III; K. Todd Newton; Tiffany Olson; Dorothy Puhy; and Martin P. Sutter (vote tallies reported in the filing).
• Executive compensation (advisory) vote: For 95,158,451; Against 4,369,645; Abstain 2,223,856 (broker non‑votes 23,609,013).
• Auditor ratification: Deloitte & Touche LLP ratified for fiscal year ending Dec. 31, 2026 — For 123,687,080; Against 1,640,474; Abstain 33,411.

Why It Matters
The bylaw change clarifies board-service limits for the CEO, which can affect time commitments and governance oversight. The annual meeting results show shareholder support for the board slate, advisory approval of executive pay (by a wide margin), and retention of Deloitte as auditor — all routine but material governance outcomes investors watch for indications of board stability and governance continuity.